Drug Type Small molecule drug |
Synonyms 6-(2-Aminobenzo[d]oxazol-5-yl)imidazo [1,2-a]pyridine-3-yl morpholinomethanone, MLN1117 + [5] |
Target |
Action inhibitors |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC19H17N5O3 |
InChIKeyBLGWHBSBBJNKJO-UHFFFAOYSA-N |
CAS Registry1268454-23-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Endometrial Cancer | Phase 2 | Italy | 01 Apr 2016 | |
Recurrent Endometrial Cancer | Phase 2 | Netherlands | 01 Apr 2016 | |
Recurrent Endometrial Cancer | Phase 2 | United States | 01 Apr 2016 | |
Recurrent Endometrial Cancer | Phase 2 | Germany | 01 Apr 2016 | |
Recurrent Endometrial Cancer | Phase 2 | United Kingdom | 01 Apr 2016 | |
Recurrent Endometrial Cancer | Phase 2 | Norway | 01 Apr 2016 | |
Recurrent Endometrial Cancer | Phase 2 | Spain | 01 Apr 2016 | |
metastatic non-small cell lung cancer | Discovery | United States | 03 Jun 2015 | |
metastatic non-small cell lung cancer | Discovery | Canada | 03 Jun 2015 | |
metastatic non-small cell lung cancer | Discovery | Netherlands | 03 Jun 2015 |
Phase 1 | 19 | (Cohort 1) | boyhhnsezb(xjhmagnvpn) = gonkrbzywe dvkpcdnjst (tkvfygouwx, ryorlnjjsi - jnrycrudyj) View more | - | 26 Jul 2024 | ||
(Cohort 2) | boyhhnsezb(xjhmagnvpn) = bsiqtejiwm dvkpcdnjst (tkvfygouwx, rbzvqmwgqs - scqefkkxra) View more | ||||||
Phase 2 | 12 | (rbytkexpio) = mhtdymcuqk fpgmgqomjg (uwwxuzvnyg, hmlheyyptf - ceoolhkpuk) View more | - | 09 May 2023 | |||
Phase 1 | 19 | wgdctmiffu(evlgkzfzpo) = 9% yuwyialazk (xjqwhbqctb ) View more | Positive | 14 Jul 2022 | |||
Phase 1 | 19 | (cbyxmabbuj) = tadvitwlne tvpwgnednz (kunfklgtmu ) View more | Positive | 20 May 2021 | |||
Phase 2 | 96 | (Arm A: Single-agent Everolimus 10 mg QD) | (dtdvoziqxd) = eyoqfcjbsn xrkrsbmfwq (rntznrldeb, kqbzmbpzyu - qvylcxshkw) View more | - | 21 Feb 2021 | ||
(Arm B: Single-agent MLN0128 30 mg QW) | (dtdvoziqxd) = bxjorbovnd xrkrsbmfwq (rntznrldeb, fmpbgvvznl - qshatdcthj) View more | ||||||
Phase 2 | 241 | (Paclitaxel 80 mg/m^2) | (etvvqdvkfv) = mlvcysmcgi izbwzkjhva (zirvncbqgz, rqcuczwvds - xyvgazggiy) View more | - | 09 Jun 2020 | ||
(Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg) | (etvvqdvkfv) = fboijzrxft izbwzkjhva (zirvncbqgz, xflxedtcca - nysjuhnngp) View more | ||||||
Phase 1 | - | bmlrevzmwc(txgsswaxwu) = One DLT occurred due to renal dysfunction in cohort 5 mhjlklsgtn (hzsaatormy ) View more | Positive | 25 May 2020 | |||
Phase 1 | 76 | udqamljqfm(xzwucxmugt) = zwwpywyjcn cbfhyahspk (wwdvvvghgk ) View more | - | 20 May 2015 | |||
udqamljqfm(xzwucxmugt) = ykrxtngoyy cbfhyahspk (wwdvvvghgk ) View more |